Johnson & Johnson Acquires Halda Therapeutics to Advance Next-Gen Oral Cancer Therapies
Johnson & Johnson Acquires Halda Therapeutics, Gaining Innovative Platform to Transform Cancer Treatment and Advance Next-Generation Oral Therapies Johnson & Johnson today announced the successful completion of its acquisition of Halda…
CRISPR Therapeutics Updates on Zugo-cel in Autoimmune & Blood Cancers
CRISPR Therapeutics Delivers Comprehensive Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) for Autoimmune Diseases and Blood Cancers CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious…
WHO Global Summit Sets a Bold Vision for the Future of Traditional Medicine
WHO Global Summit Forges a Bold Vision for the Future of Traditional Medicine The second WHO Global Summit on Traditional Medicine, jointly organized with the Government of India, concluded today in New Delhi,…
Japan Approves Finerenone for Chronic Heart Failure Treatment
Finerenone Receives Approval in Japan for Chronic Heart Failure Treatment Bayer today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved finerenone (Kerendia™), a non-steroidal, selective mineralocorticoid…
Pimicotinib Approved in China as First Systemic Therapy for Tenosynovial Giant Cell Tumor
Pimicotinib Gains Approval in China as First Systemic Therapy for Tenosynovial Giant Cell Tumor Merck, a leading science and technology company, announced today that following Priority Review, the China National…
FDA Approves Subcutaneous Use of Roche’s Lunsumio VELO™ for Relapsed or Refractory Follicular Lymphoma
FDA Approves Subcutaneous Form of Roche’s Lunsumio VELO™ for Relapsed or Refractory Follicular Lymphoma Roche announced today that the US Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio…
Novo Nordisk’s Wegovy® Becomes First Oral GLP-1 Approved in the U.S. for Weight Management
Novo Nordisk’s Wegovy® Becomes First Oral GLP-1 Therapy Approved in the U.S. for Weight Management Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the…
EC Approves TREMFYA® for Pediatric Plaque Psoriasis — First IL-23 Inhibitor for Children
EC approves TREMFYA® for pediatric plaque psoriasis — first IL-23 inhibitor for children Johnson & Johnson today announced that the European Commission (EC) has extended the marketing authorisation for TREMFYA® (guselkumab) as…
Cytokinetics Announces FDA Approval of MYQORZO™ for Symptomatic oHCM
Cytokinetics Announces FDA Approval of MYQORZO™ for Symptomatic Obstructive HCM in Adults Cytokinetics, Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™, 5 mg, 10 mg,…
BioMarin to Acquire Amicus Therapeutics in $4.8 Billion Deal, Bolstering Leadership in Rare Diseases and Driving Growth
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Bolstering Leadership in Rare Diseases, Driving Revenue Growth, and Enhancing Financial Outlook BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin…
WuXi Biologics Earns Top “A” Ratings from CDP for Climate Change and Water Security
WuXi Biologics Earns Top “A” Ratings from CDP for Climate Change and Water Security WuXi Biologics announced that it has been named to the CDP “A” lists for both Climate…
Merck Strikes Deal with U.S. Government to Broaden Medicine Access and Reduce Costs for Americans
Merck Strikes Deal with U.S. Government to Broaden Access to Medicines and Reduce Costs for Americans Merck, known as MSD outside of the United States and Canada, today announced a…